| Dendreon Insiders Cash In on Drug Approval CEO Mitchell Gold sold more than $28 million of Dendreon stock and other company officials also sold shares in the hours after the FDA approved the cancer treatment Provenge. online.wsj.com |
J&J Plant Closing to Continue Johnson & Johnson said it won't reopen a Pennsylvania production plant that makes children's medicines before the end of this year. online.wsj.com |
Probe: China Didn't Investigate Heparin A congressional probe says China didn't pursue an investigation into contaminated heparin sent to the U.S. in 2007 and 2008, despite suggestions from U.S. officials that it did. online.wsj.com |
ImmunoGen Suffers From the Second Lethal Virus Prohost Biotech submits:Two lethal viruses plague general investors. The euphoria virus infects investors when the market stages sustained rallies. This virus makes investors buy and buy until the balloon becomes overstretched and eventually bursts. The fear virus causes hysteria in susceptible investors when their stocks go south and rush them to sell at ridiculously low prices. The fear virus also provokes vulnerable investors to immediately dispose of their stocks at the hint of unfavorable news, whether or not the negative news is indicative of weakness in the firms’ fundamentals. Healthy, rational investors usually take advantage to accumulate the battered stocks of firms with strong fundamentals at the new bargain price that results from sell-offs by the fearful. A case in point: Immunogen (IMGN)Complete Story » seekingalpha.com |
Immunogen's T-DM1 Gets Presidential Treatment Ohad Hammer submits:Immunogen (IMGN) is still trying to recuperate from the controversial rejection of T-DM1's accelerated approval filing. The message Immunogen was trying to convey is that nothing has changed in terms of T-DM1's long term potential. According to the company, the FDA's problem was not with the drug's stellar activity but the patient population enrolled on the trial. In just over a week from now, it could have the data to prove it.Although the next potential filing is expected only in 2012 based on an ongoing phase III trial (EMILA study), T-DM1 will have two important data read-outs at next month's ESMO conference. The first is a phase II study where it is compared to chemotherapy+ Herceptin, the current standard of care for 1st line breast cancer patients. As I reviewed last month, expectations from this trial are high given Roche's (RHHBY.PK) decision to start a pivotal trial based on a similar trial design.Complete Story » seekingalpha.com |